Visit COVID-19 resources

[Skip to Content]

Hydroxychloroquine

Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring

Updated Guidelines December 2020 Following the publication of the RCOphth recommendations for monitoring in hydroxychloroquine and chloroquine users in 2018, new published evidence prompted a review of the guideline. Recent data have highlighted that hydroxychloroquine retinopathy is more common than previously reported. The prevalence in long-term users appears to be around 7.5% and depending on

RCOphth guideline: Hydroxychloroquine and Chloroquine Retinopathy: NEW screening recommendations February 2018

The new guideline on screening for hydroxychloroquine and chloroquine retinopathy is written in response to evidence from the United States that shows that hydroxychloroquine retinopathy is more common than previously recognised. Implementation of the guideline’s recommendations will prevent iatrogenic visual loss. The new guideline also makes recommendations regarding the techniques and timing of baseline and